Skip to main content
Stergios J Moschos on Muck Rack

Stergios J Moschos

As seen in: The BMJ, Cell Press, OncLive
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Stergios J

Contact Stergios J, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Intra-tumoral hypoxia promotes CD8+ T cell dysfunction via chronic activation of integrated stress response transcription factor ATF4

|
By Brian Riesenberg, Evelyn Gandy, Andrew Kennedy, Genevieve Clutton, Jessica W. Hem, Katie Hurst, Elizabeth G. Hunt, Brian Miller, Steven P Angus, Gary Johnson, Robert J. Esther, Jennifer L. Guerriero, Peng Gao, David R. Soto-Pantoja, Robert Ferris Verified, Jennifer L Modliszewski, Michael Coleman, H. Kay Chung, J. Justin Milner, Stergios J Moschos, R. Luke Wiseman, Jessica E. Thaxton
| Cell Press Verified
Keywords T cell immunotherapy tumor microenvironment hypoxia integrated stress response ATF4 mitochondria metabolism Introduction Cancer poses a significant challenge to global public health and is the second leading cause of mortality in the United States.1 Conventional cancer treatments include surgery, chemotherapy, and radiation therapy; however, these treatments are hampered by drug resistance, severe toxicities, and limited efficacy.2 The development of immune checkpoint inhibitor (ICI)...
Open in Who Shared Issue with article?

1465 Denosumab improves clinical benefit of PD1 inhibitors in metastatic melanoma (MM) presumably via a suppressive effect on immunoregulatory myeloid cell populations | Journal for ImmunoTherapy of Cancer

|
By David W. Ollila, Paul Googe, Monica Cappelletti, Stergios J Moschos
| The BMJ Verified
Late-Breaking Abstracts Clinical Trial Completed 1465 Denosumab improves clinical benefit of PD1 inhibitors in metastatic melanoma (MM) presumably via a suppressive effect on immunoregulatory myeloid cell populations Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service.
Open in Who Shared View Duplicates (154) Issue with article?
See all 2 licensed articles (3 Total)